Coloplast

Multiple silver linings in spite of a soft Q2 24

15/05/24 -"Coloplast reported softer than expected Q2 24 figures. However, with healthy organic growth, the miss reflected FX headwinds, and, hence, was not that worrisome. Importantly, growth was strong across ..."

PDF page sample
Pages
62
Language
English
Published on
15/05/24
Download
You may also be interested by these reports :
05/09/24
bioMerieux’s Q2 sales exceeded expectations. Double-digit growth was led by healthy contributions from both segments. Even 2024 guidance was ...
03/09/24
Following the company’s profit warning, we have cut our 2024 EBITDAR forecast from €822m to €728m (-11.4%), mainly to reflect the tougher ...
30/08/24
Bastide posted stronger qoq organic growth in Q4 and guidance-beating FY revenue, with the more technical activities continuing to lead the revenue ...
29/08/24
Smith & Nephew reported mixed headline Q2 24 figures, missing at the top line but beating on profitability. However, the firm registered acceleration ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO